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Key Points 
 Liver carcinogenesis represents a paradigm to study the role of the 
microenvironment in cancer given that most tumors develop in a background of 
liver fibrosis/cirrhosis 
 Tumor cell microenvironment remodeling is associated with tumor progression 
 HSC play an important role in liver carcinogenesis as key modulators of fibrosis 
and tumor cell microenvironment 
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 Targeting HSC and the crosstalk between tumor and stromal cells may represent 
a promising therapeutic strategy 
 
Summary 
Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) are the 
most common types of primary tumors in the liver. Although major advances have been 
made in understanding the cellular and molecular mechanisms underlying liver 
carcinogenesis, HCC and ICC are still deadly cancers worldwide waiting for innovative 
therapeutic options. Growing evidences from the literature highlight the critical role of 
the tumor cell microenvironment in the pathogenesis of cancer diseases. Thus, 
targeting the microenvironment, particularly the crosstalk between tumor cells and 
stromal cells, has emerged as a promising therapeutic strategy. This strategy would be 
particularly relevant for liver cancers which frequently develop in a setting of chronic 
inflammation and microenvironment remodeling associated with hepatic fibrosis and 
cirrhosis, such processes in which hepatic stellate cells (HSC) greatly contribute. This 
review brings a genomic point of view on the alterations of the cellular 
microenvironment in liver cancers, particularly the stromal tissue within tumor nodules, 
emphasizing the importance of the crosstalk between tumor cells and stromal cells, 
notably activated HSC, in tumor onset and progression. Furthermore, potential 
therapeutic modalities of targeting the stroma and HSC are discussed. 
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Introduction 
Growing evidences from genetic, genomic and cell-biology indicate that tumorigenesis 
is determined not only by malignant cells but also by their microenvironment [1]. The 
microenvironment is a complex and dynamic system involving extracellular matrix 
(ECM) components, soluble factors, and stromal cells, whose distribution and 
composition vary in space and time [1-3]. Under physiological condition, the 
microenvironment serves as an important barrier to epithelial cell transformation, 
notably by maintaining cell polarity and by controlling cell proliferation [1-3]. In response 
to emerging epithelial cancerous lesions, the microenvironment experiences important 
changes (e.g. recruitment/activation of stromal cells, ECM remodeling) which contribute 
to cancer initiation and progression and influence the therapeutic response [1-3]. Thus, 
targeting the tumor microenvironment is now viewed as a promising strategy to treat 
cancer in a variety of organs including liver [3-4]. Hepatocellular carcinoma (HCC) and 
intrahepatic cholangiocarcinoma (ICC) are the two major types of primary tumors in the 
liver. Alteration of the microenvironment is a hallmark of liver carcinogenesis given that 
more than 80% of tumors arise in a setting of chronic inflammation associated with liver 
fibrosis and/or cirrhosis, such conditions which constitute real precancerous stages [4]. 
As key drivers of liver fibrosis and ECM remodeling [5], activated hepatic stellate cells 
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(HSC) might represent attractive targets in the design of innovative therapeutic 
strategies against the stroma in liver carcinogenesis. 
 
The tumor microenvironment in liver carcinogenesis 
Tumor microenvironment includes cellular and non-cellular components. In the liver, 
HSC, fibroblasts, myofibroblasts as well as immune and endothelial cells represent the 
main cell types of the hepatocyte microenvironment [4]. In addition to ECM 
macromolecules (e.g. collagens, proteoglycans), non-cellular components include 
diverse soluble factors such as cytokines and growth factors that can be stored into the 
ECM and orchestrate the interplays between tumor cells and the microenvironment [1-
4].  
Combination of cell and molecular biology, biochemistry, histopathology and gene to 
gene approaches greatly contributed to identify pathways deregulated in the tumor 
stroma and their impact on tumor cells [1]. Recently, genomic approaches revisited the 
field allowing an exhaustive and integrated view of these deregulations at a pangenomic 
scale [6]. Even more, by combining laser microdissection and gene expression profiling, 
stromal gene signatures linked to clinical outcomes were established in cancer [6]. This 
approach was proven to be fruitful for deciphering the molecular mechanisms 
underlying the alterations of the tumor microenvironment, with the ultimate goal of 
designing new therapeutic approaches, and identifying novel diagnostic and prognostic 
biomarkers [6]. In liver, few studies addressed this issue at a genomic scale. In HCC, 
gene expression profiling highlighted the importance of Th1 and Th2 cytokines in the 
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surrounding non-tumor tissue of HCC associated with metastasis [7]. A metastasis-
inclined microenvironment signature was characterized by an increase in Th2 cytokines 
and a decrease in Th1 cytokines [7]. This study suggested that the dynamics of the 
immune microenvironment in the non-tumor tissue adjacent to the tumor nodules may 
result in the establishment of a suitable niche to promote tumor cell dissemination. 
Genomic studies also provided molecular insights into the pathogenesis of ICC which is 
usually characterized by a dense desmoplastic stroma [8]. From these studies clinically 
relevant ICC subgroups were highlighted and new therapeutic opportunities were 
proposed, based on BRAF/KRAS mutations and activation of oncogenic pathways (e.g. 
receptor tyrosine kinases) [8]. Recently, we identified specific alterations of the stroma 
in ICC through an unsupervised analysis of microdissected human tumors [9]. Thus, a 
signature which included genes related to cell cycle, ECM and transforming growth 
factor beta (TGFβ) pathways was shown to significantly discriminate the tumor stroma 
from fibrous tissue isolated in the adjacent non tumor liver. A clear correlation between 
genomic changes in the stroma and the aggressiveness of ICC was also demonstrated. 
Notably, high stromal expressions of osteopontin and TGFβ were identified as poor 
prognosis factors [9]. Besides promising biomarkers, osteopontin and TGFβ represent 
potential therapeutic targets given their proven role in driving the oncogenic process, 
from early stages of tumor development to late invasive stages. Indeed, gain and loss of 
function studies demonstrated osteopontin to be crucial for tumor cell growth and 
metastasis, notably by mechanisms involving apoptosis escape, angiogenesis, and 
ECM degradation [10]. Activation of the TGFβ signaling was found in HCC [11], ICC [9] 
and combined HCC-ICC [12]. Importantly, studies using engineered mice demonstrated 
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that the modulation of the TGFβ pathway in stromal fibroblasts influence the oncogenic 
potential of the adjacent epithelial cells [2]. These results imply that genomic alterations 
in stromal cells may result in tumor initiation and progression. 
 
HSC in tumor onset and progression  
The activation of HSC and subsequent phenotypic changes towards a myofibroblast-like 
phenotype is a key event in liver fibrosis [5]. Gene expression studies showed that 
activated HSC markedly express genes involved in fibrogenesis and fibrolysis, 
inflammation and apoptosis [13]. HSC activation is controlled by numerous factors and 
signaling pathways (e.g. TGFβ, platelet-derived growth factors (PDGF), hedgehog, 
notch, microRNAs) [5]. Recently, the hedgehog signaling was shown to control the fate 
of HSC, thus opening new opportunities for a therapeutic targeting of HSC [14]. The 
nuclear factor-kappa B (NF-κB) pathway has been also reported to contribute to HSC 
activation and survival, and more largely to be a central factor in the progression of 
hepatic diseases, linking liver injury, inflammation, fibrosis and HCC (reviewed in [15]).   
Besides a major role in fibrogenesis, HSC exhibit biological functions that influence the 
onset and the progression of HCC [5]. Thus, HSC can induce phenotypic changes in 
cancer cells, notably through the production of growth factors and cytokines in favor of 
tumor cell proliferation (e.g. hepatocyte growth factor, interleukin-6 (IL-6)) [5,16]. 
Migration and proliferation of HCC cells are also modulated by ECM components 
produced by activated HSC, including basement membrane components, e.g. laminin-5 
[17]. Interestingly, HSC were reported as key players in liver tumorigenesis associated 
8 
 
with the gut-liver axis [18]. Thus, the gut microbiome was shown to induce inflammatory 
and fibrogenic responses, and HSC activation leading to the production of epiregulin, a 
mitogenic factor for hepatocytes [18]. Cellular and molecular approaches demonstrated 
that a bidirectional crosstalk exists between HSC-derived myofibroblasts and tumor 
hepatocytes [5]. Early studies showed that the exposition of HSC to conditioned media 
derived from HCC tumor cells resulted in HSC activation, migration and expression of 
pro-angiogenic factors such as vascular endothelial growth factor alpha (VEGFA) [5]. 
Recently, we reported that the crosstalk between hepatoma cells and activated HSC 
also increased the expression of proinflammatory cytokines and chemokines (e.g. IL-6, 
IL-8), and modified the phenotype of hepatoma cells toward motile cells, together with 
the generation of a permissive pro-angiogenic microenvironment, characterized by the 
overexpression of VEGFA and matrix metallopeptidase 9 (MMP9) in HSC [19]. 
Interestingly, integrative genomics demonstrated that a gene signature of this crosstalk 
was predictive of a poor prognosis and metastasis propensity in human HCC [19]. In 
addition to pro-inflammatory cytokines, TGFβ was reported to be central in driving the 
pro-tumorigenic effects of activated HSC on the progression of transformed hepatocytes 
[20]. Interplay between HSC and cancer cells has been also reported in ICC, notably 
through the SDF1/CXCR4 axis which activation was shown to influence both cancer cell 
survival and metastasis [20]. In addition to early stages of tumor development, HSC are 
involved in late tumor stages, notably by producing factors that directly participate in the 
formation of a pro-metastatic microenvironment [16]. Such factors in favor of the 
metastatic growth of tumor cells include inducers of the epithelial to mesenchymal cell 
transition (EMT), modulators of ECM synthesis and degradation, pro-angiogenic and 
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immune-suppression factors (e.g. TGFβ, ECM proteins, MMP, VEGFA) [16]. HSC can 
produce immune-regulatory cytokines (e.g. MCP1, RANTES, CCL21) to promote 
chemotaxis, adherence and activation of inflammatory cells [5,22]. Paracrine 
interactions of HSC with endothelial cells have been reported, as well as the secretion 
of VEGFA and angiopoietins by HSC favoring a pro-angiogenic microenvironment [22]. 
 
Therapeutic targeting of tumor microenvironment and HSC 
Targeting the microenvironment is emerging as a promising strategy given the well-
recognized role of the stroma in carcinogenesis [3]. Examples of drugs targeting the 
microenvironment include anti-angiogenic and anti-proliferative agents such as 
bevacizumab, an inhibitor of VEGFA, cetuximab, an inhibitor of EGFR, and sorafenib, 
an inhibitor of multiple protein kinase receptors (e.g. EGFR, VEGFR, PDGFR) [4]. 
Interestingly, sorafenib, which is currently the only drug recommended for advanced 
HCC, was shown to reduce the proliferation of transformed hepatocytes but also to 
attenuate liver fibrosis, notably by reducing HSC proliferation and ECM accumulation 
[23]. This observation opens an opportunity to target not only the tumor cells but also 
their microenvironment. One can expect that a better understanding of the cellular and 
molecular mechanisms underlying the process of HSC activation/proliferation, and ECM 
remodeling associated with tumor onset and progression may open opportunities to 
design new lines of therapeutic approaches. Therapeutic targeting of HSC has been 
investigated with interest given the key role HSC in fibrosis and HCC [22]. Induction of 
cellular apoptosis or senescence and reversion of activated HSC toward a quiescent 
10 
 
state have been proposed as mechanisms to clear activated HSC [22]. As example, 
selective induction of HSC apoptosis may be achieved by nanoparticules or gene 
transfer systems designed to inhibit NF- B transcription factor which controls HSC 
activation and proliferation [15]. Boosting specific immune cell populations may 
represent another innovative strategy to control HSC. Recently, hepatic T-cells have 
been shown to promote the apoptosis of HSC through a mechanisms involving Fas-
ligand [24]. NK cells have been also shown to selectively kill early or senescent 
activated HSC and to produce anti-fibrotic cytokines such as IFN  [22]. Among immune 
effectors which exhibit anti-fibrotic potentials (e.g. IFN , IL-22, IL-10), IL22 was reported 
as a potent inducer of HSC senescence [22].  
Targeting the crosstalk between tumors cells and their microenvironment may also 
represent a promising therapeutic strategy. Exploring this possibility, we recently 
applied an integrative functional genomics approach to identify molecules that could 
interfere with the crosstalk between hepatocytes and HSC [19]. Thus, by using a 
connectivity map algorithm we were able to connect a gene signature of the hepatocyte-
HSC crosstalk with trichostatin A, an inhibitor of histone deacetylases. Accordingly, the 
effects of the crosstalk on tumor cell migration and endothelial cell angiogenesis were 
reversed in presence of trichostatin A, suggesting that epigenetic modulators may be 
clinically relevant [19]. Soluble factors may be also targeted to modulate the 
communication between the tumor cells and the microenvironment. In that regard, 
TGF  may represent a promising target given that this cytokine is involved in multiple 
stages of liver carcinogenesis. TGF  exhibits both oncogenic and tumor suppressive 
properties depending on tumor stage [11,25]. As mentioned above, at preneoplastic 
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stages TGF  acts as a potent inducer of HSC activation and fibrogenesis but also 
exhibits growth-inhibitory and apoptosis-inducing effects, and in advanced stages 
TGF promotes HCC/ICC tumor cell invasion, notably as an inducer of EMT [11,25]. 
Thus, therapeutic targeting of the TGF  pathway should be appropriately designed to 
inhibit its oncogenic properties while retaining its cytostatic effects. Targeting the TGF  
signaling by using small molecule inhibitors (e.g. LY2109761) or neutralizing antibodies 
has shown promising results in experimental HCC mouse models, including inhibition of 
cell invasion and abrogation of neo-angiogenesis [25]. Inhibition of the TGF  signaling 
was also reported to be effective in blocking tumor-stroma crosstalk and tumor 
progression in HCC [25]. Thus, appropriately interfering with the crosstalk between 
cancer cells and their microenvironment may open new therapeutic opportunities in liver 
cancers (Figure 1).  
 
Conclusive remark 
Advances in understanding the molecular mechanisms involved in the crosstalk 
between tumor cells and their microenvironment at the pangenomic scale open the path 
to design new lines of therapeutic approach and associated biomarkers. Recent findings 
highlight that future adapted therapeutics would target both the tumor cells and the 
microenvironment by favorably modulating specific regulators in cellular pathways, and 
widespread mechanisms related to the neoplastic stroma evolution. 
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Figure legend. 
Figure 1. Therapeutic potential of targeting HSC and the stroma in liver cancer. 
Depicted are the interplays between tumors cells and components of the 
microenvironment, notably HSC, which influence tumor progression by creating a 
permissive environment and by perverting the phenotype of tumor cells. Each of these 
interactions, symbolized by arrows, could be targeted for therapeutic purpose. 
Epigenetic modulation of the crosstalk between tumor cells and their microenvironment 
may also open new therapeutic opportunities in liver cancers. 
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